- Trials with a EudraCT protocol (93)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
93 result(s) found for: Vitreous.
Displaying page 1 of 5.
EudraCT Number: 2009-015559-25 | Sponsor Protocol Number: KCH1724 | Start Date*: 2010-04-22 | |||||||||||
Sponsor Name:King's College Hospital NHS Foundation Trust | |||||||||||||
Full Title: Preoperative intravitreal ranibizumab for persistent diabetic vitreous haemorrhage: A randomized, double-masked, controlled study | |||||||||||||
Medical condition: Retinopathy is a well recognised complication of diabetes and is a leading cause of vision loss in this patient group. The severity of diabetic retinopathy varies, but in its most severe form (pro... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000780-21 | Sponsor Protocol Number: CHEF1005 | Start Date*: 2007-10-12 |
Sponsor Name:Moorfields Eye Hospital | ||
Full Title: A randomised, single-masked, Phase IV pilot study of the efficacy and safety of adjunctive intravitreal Avastin® (bevacizumab) in the prevention of early postoperative vitreous haemorrhage followin... | ||
Medical condition: Vitreous haemorrhage secondary to proliferative diabetic retinopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-000388-41 | Sponsor Protocol Number: OZR-2013-27 | Start Date*: 2014-05-05 |
Sponsor Name:The Rotterdam Eye Hospital | ||
Full Title: Does oral administration of dabigatran etexilate, a direct thrombin inhibitor, achieve clinical significant concentrations of dabigatran and thrombin inhibiting activity in vitreous and subretinal ... | ||
Medical condition: Ocular accessibility of dabigatran in patients with retinal detachment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-018919-16 | Sponsor Protocol Number: TG-MV-010 | Start Date*: 2010-06-28 | |||||||||||
Sponsor Name:ThromboGenics NV | |||||||||||||
Full Title: An Open-Label, Ascending- Exposure-Time, Single Center Trial to Evaluate the Pharmacokinetic Properties of Ocriplasmin (Generic Name of the Molecule Microplasmin) Intravitreal Injection in Subjects... | |||||||||||||
Medical condition: Patients who require primary pars plana vitrectomy. A sample of vitreous will be taken at beginning of surgery for PK analysis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003297-81 | Sponsor Protocol Number: PDRPOZU1 | Start Date*: 2011-09-12 | |||||||||||
Sponsor Name:St Eriks Eye Hospital | |||||||||||||
Full Title: A prospective, randomized study on intravitreal Ozurdex for preventing recurrent vitreous hemorrhage following pars plana vitrectomy for proliferative diabetic retinopathy | |||||||||||||
Medical condition: Proliferative diabetic retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000736-26 | Sponsor Protocol Number: 206207-014 | Start Date*: 2006-05-17 |
Sponsor Name:Allergan Limited | ||
Full Title: An 8-Week, Multicenter, Masked, Randomized Trial (with an 18-Week Masked Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX ... | ||
Medical condition: Non-infectious ocular inflammation of the posterior segment in intermediate or posterior uveitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) AT (Completed) IT (Completed) PT (Completed) BE (Completed) CZ (Completed) DE (Completed) GR (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-001622-29 | Sponsor Protocol Number: ALI-P01-21-006 | Start Date*: 2023-03-01 | |||||||||||
Sponsor Name:Alimera Sciences Europe Limited | |||||||||||||
Full Title: A NON-RANDOMISED, OPEN-LABEL, UNCONTROLLED, MULTI-CENTRE, PHASE IIIB STUDY EVALUATING THE SAFETY AND EFFICACY OF FLUOCINOLONE ACETONIDE 190 MICROGRAMS INTRAVITREAL IMPLANT IN PAEDIATRIC SUBJECTS FR... | |||||||||||||
Medical condition: Non-Infectious Uveitis affecting the posterior segment | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001595-19 | Sponsor Protocol Number: 32-007 | Start Date*: 2011-11-18 | |||||||||||
Sponsor Name:SANTEN INCORPORATED | |||||||||||||
Full Title: A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infec... | |||||||||||||
Medical condition: Uveitis of the Posterior Segment of the Eye. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) DE (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006085-42 | Sponsor Protocol Number: TG-MV-004 | Start Date*: 2007-01-24 | |||||||||||
Sponsor Name:ThromboGenics Ltd. | |||||||||||||
Full Title: A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding, Multicenter Trial of Microplasmin Intravitreal Injection for Non-Surgical PVD Induction for Treatment of ... | |||||||||||||
Medical condition: Vitreomacular Traction Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006543-31 | Sponsor Protocol Number: LX211-01-UV | Start Date*: 2007-04-13 | |||||||||||
Sponsor Name:Lux Biosciences GmbH | |||||||||||||
Full Title: A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study with an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight ... | |||||||||||||
Medical condition: Subjects with active sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004160-30 | Sponsor Protocol Number: CFTY720D2205 | Start Date*: 2013-05-08 | |||||||||||
Sponsor Name:Novartis Pharma Service AG | |||||||||||||
Full Title: A multicenter, randomized, active-controlled study to assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis | |||||||||||||
Medical condition: Uveitis, intermediate; uveitis, posterior; uveitis, pan. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001421-55 | Sponsor Protocol Number: CRFB002GFR02 | Start Date*: 2013-06-13 | |||||||||||
Sponsor Name:Novartis Pharma S.A.S | |||||||||||||
Full Title: An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases. | |||||||||||||
Medical condition: Choroidal neovascularization not related to wet Age-related macular degeneration (wAMD), pathologic myopia (PM)or Pseudoxanthoma elasticum (PXE), as well as in Macular Edema (ME) not related to Ret... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003653-16 | Sponsor Protocol Number: S62092 | Start Date*: 2019-03-21 | |||||||||||
Sponsor Name:UZ Leuven | |||||||||||||
Full Title: Abatacept in patients with Birdshot HLA A29 uveitis: A Phase II Prospective 0pen Label Interventional Proof-of-Concept Study | |||||||||||||
Medical condition: Birdshot Uveitis HLA A29 retinochoroiditis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004488-38 | Sponsor Protocol Number: ILV-001 | Start Date*: 2017-12-28 |
Sponsor Name:J. W. Goethe University, represented by dean of the medical faculty | ||
Full Title: Iluvit – An investigator initiated monocentric pilot study to investigate inflammation parameters and growth factors in the vitreous during a cortisone long-term therapy with Iluvien® in patients w... | ||
Medical condition: Diabetic related Macula edema | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-002351-33 | Sponsor Protocol Number: 1299 | Start Date*: 2006-08-09 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA | |||||||||||||
Full Title: Evaluation of safety and efficacy of intravitreal bevacizumab for macular edema, retinal or choroidal neovascularization or neovascular glaucoma | |||||||||||||
Medical condition: Macular oedema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018737-21 | Sponsor Protocol Number: Studio PROP-ROP | Start Date*: 2010-02-25 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA MEYER | |||||||||||||
Full Title: Safety and efficacy of treatment with propranolol in newborns suffering from rethinopathy of the preterm: a pilot study | |||||||||||||
Medical condition: Retinopathy of the preterm | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003029-40 | Sponsor Protocol Number: IOBA-01-2016 | Start Date*: 2017-02-14 |
Sponsor Name:IOBA - University of Valladolid | ||
Full Title: Phase II safety assessment of intravitreal injection of mesenchymal stem cells for acute non arteritic anterior ischemic optic neuropathy (NAION) | ||
Medical condition: Non arteritic anterior ischemic optic neuropathy (NAION) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003640-23 | Sponsor Protocol Number: ECR-RET-2013-05 | Start Date*: 2014-01-13 | |||||||||||
Sponsor Name:AIBILI - Association for Innovation and Biomedical Research on Light and Image | |||||||||||||
Full Title: Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP ... | |||||||||||||
Medical condition: Patients with type I or type II diabetes mellitus and high risk diabetic retinopathy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004626-93 | Sponsor Protocol Number: TG-MV-002 | Start Date*: 2006-12-19 | |||||||||||
Sponsor Name:ThromboGenics N.V. | |||||||||||||
Full Title: A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical PVD Induction for Treatment of Diabetic Macu... | |||||||||||||
Medical condition: Diabetic macular edema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) NL (Completed) GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003254-90 | Sponsor Protocol Number: CLFG316A2204 | Start Date*: 2012-05-14 | ||||||||||||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||||||||||||
Full Title: A randomised, active-controlled, open-label, multiple-dose, proof-of-concept study of intravitreal LFG316 in patients with active non-infectious intermediate-, posterior-, or panuveitis requiring s... | ||||||||||||||||||||||||||||
Medical condition: Active non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
